Medpace (NASDAQ:MEDP) Shares Gap Down – Time to Sell?

Medpace Holdings, Inc. (NASDAQ:MEDP) gapped down prior to trading on Tuesday . The stock had previously closed at $530.35, but opened at $489.00. Medpace shares last traded at $456.5890, with a volume of 184,772 shares trading hands.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q4 results beat consensus — EPS of $4.67 vs. $4.18 expected and revenue of $708.5M (up 32% YoY). Strong margins and ROE reinforce the quality of the quarter. Business Wire: Q4 & FY2025 Results
• Positive Sentiment: Management provided FY‑2026 guidance above prior expectations — EPS range 16.68–17.50 and revenue guide ~$2.8–2.9B, signaling continued high-single/low‑double‑digit growth visibility. (Guidance underpins upside to 2026 earnings). Business Wire: Guidance Details
• Neutral Sentiment: Earnings call color — management reiterated drivers (therapeutic mix, international growth, disciplined buybacks) but gave detail that some analysts view as mixed; read the full call transcript for nuance on bookings and timing. Seeking Alpha: Q4 2025 Call Transcript
• Negative Sentiment: Backlog and booking dynamics flagged as concern — analysts and commentaries describe backlog growth as “stale/sluggish,” which tempers confidence in sustained revenue acceleration despite a healthy book‑to‑bill. That narrative pressured the stock. Seeking Alpha: Great Quarter, Stale Backlog
• Negative Sentiment: Market reaction and headlines highlighted a “key negative” (timing/contract mix impact and perceived in‑line elements of guidance), triggering short‑term profit taking despite the beat — several outlets noted the stock dropped on the news. Investing.com: Shares Tumble Despite Beat MSN: Key Negative Explained

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on MEDP. Robert W. Baird set a $613.00 price objective on shares of Medpace in a report on Friday, October 24th. Mizuho set a $660.00 price target on shares of Medpace in a research note on Friday, January 9th. TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. Finally, BMO Capital Markets started coverage on Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Stock Down 15.2%

The business has a fifty day moving average of $578.30 and a 200 day moving average of $539.57. The firm has a market cap of $12.67 billion, a P/E ratio of 31.53, a PEG ratio of 1.82 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue was up 32.0% on a year-over-year basis. During the same period last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. The trade was a 0.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $3,542,100. The trade was a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 302,192 shares of company stock worth $182,019,762 over the last quarter. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Norges Bank acquired a new position in Medpace during the 2nd quarter worth approximately $66,597,000. Arrowstreet Capital Limited Partnership lifted its stake in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Clarkston Capital Partners LLC acquired a new stake in Medpace in the second quarter valued at approximately $40,569,000. Finally, Mawer Investment Management Ltd. grew its stake in shares of Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after buying an additional 121,213 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.